News >

Expert Highlights Potential of Moxetumomab Pasudotox in Hairy Cell Leukemia

Brandon Scalea
Published: Tuesday, Jul 17, 2018

Robert J. Kreitman, MD

Robert J. Kreitman, MD
Moxetumomab pasudotox, a recombinant immunotoxin that targets CD22, demonstrated significant clinical activity in patients with relapsed/refractory hairy cell leukemia, according to findings from an international phase III trial presented at the 2018 ASCO Annual Meeting.

Hairy cell leukemia is a rare B-cell malignancy distinguished by high CD22 expression. When moxetumomab, fused with a p38 toxin, binds to CD22 and internalizes, it inhibits protein synthesis and leads to cell death, explained lead author, Robert J. Kreitman, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication